Check for updates

RESEARCH NOTE

Abnormal expression of *ATP1A1* and *ATP1A2* in breast cancer**[version 1; peer review: 2 approved]**Alexey Bogdanov ¹⁻⁴, Fedor V. Moiseenko^{1,2}, Michael Dubina¹⁻³¹St Petersburg Academic University, St. Petersburg, Russian Federation²Practical Center for Specialized Types of Medical Care (Oncologic), St-Petersburg, Russian Federation³Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russian Federation⁴The Petersburg Nuclear Physics Institute, Gatchina, Russian Federation**V1** First published: 05 Jan 2017, 6:10
<https://doi.org/10.12688/f1000research.10481.1>Latest published: 05 Jan 2017, 6:10
<https://doi.org/10.12688/f1000research.10481.1>**Abstract**

Breast cancer is the first in incidence and the second in death among all solid tumors occurring in women. The identification of molecular genetic abnormalities in breast cancer is important to improve the results of treatment. In the present study, we analyzed microarray data of breast cancer expression profiling (NCBI GEO database, accession [GSE65194](#)), focusing on Na⁺/K⁺-ATPase coding genes. We found overexpression of the *ATP1A1* and down-regulation of the *ATP1A2*. We expect that our research could help to improve the understanding of predictive and prognostic features of breast cancer.

Keywordsbreast cancer , Na⁺/K⁺-ATPase , gene expression , abnormality , ATP1A1 , ATP1A2**Open Peer Review****Approval Status**

	1	2
version 1
05 Jan 2017	view	view

1. **Mikhail Fedyanin**, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation

2. **Jen-Tsan Ashley Chi**, Duke University Medical Center, Durham, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding authors: Alexey Bogdanov (aleks_aa@mail.ru), Fedor V. Moiseenko (moiseenkofv@gmail.com)

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by The Ministry of Education and Science of Russian Federation (unique identifier of applied research: RFMEFI60414X0070)

Copyright: © 2017 Bogdanov A *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Bogdanov A, Moiseenko FV and Dubina M. **Abnormal expression of *ATP1A1* and *ATP1A2* in breast cancer [version 1; peer review: 2 approved]** F1000Research 2017, 6:10 <https://doi.org/10.12688/f1000research.10481.1>

First published: 05 Jan 2017, 6:10 <https://doi.org/10.12688/f1000research.10481.1>

Introduction

Breast cancer is one of the most common and deadly female solid tumors¹. According to reports from Perou *et al.*², further confirmed by other investigators^{3,4}, breast cancer is a highly molecularly heterogeneous disease. The identification of molecular genetic abnormalities in breast cancer is important to improve the results of treatment and, for instance, to reveal new targets for specific therapies. Recent studies based on original retrospective analysis of digitalis use in breast cancer patients have demonstrated the anticancer effect of cardiac glycosides⁵ that directly inhibit Na⁺/K⁺-ATPase (NKA) activity. NKA signaling functions after interaction with cardiac glycosides were also shown⁶. It seems rational that expression of NKA might influence breast cancer prognosis.

NKA is a significant integral membrane protein. NKA's main function is the creation and maintenance of electrochemical gradients for sodium and potassium ions in the living cell. These gradients have critical importance for control of cell volume, osmolarity and resting potential^{7,8}. The minimal functional NKA consists of two associated alpha- and beta- subunits. The catalytic alpha-subunit is responsible for conversion of ATP energy to transport of Na⁺ and K⁺ across cell membranes and has ATP and cardiac glycosides binding sites. It may be present in human tissues in four different isoforms ($\alpha 1$, $\alpha 2$, $\alpha 3$, $\alpha 4$ – found only in testicles). The beta-subunit is responsible for delivery and insertion of alpha one in cell membranes and has three distinct isoforms in humans ($\beta 1$, $\beta 2$, $\beta 3$)^{8–10}. NKA subunits are variably expressed in different human tissues¹¹. Changes in the relative expression between different isoforms are associated with a number of pathological processes including malignant transformation^{12,13}. Both down- and up-regulation of alpha- and beta- subunits were shown in solid tumors of different origin^{14–19}.

In the present study, we analyzed public breast cancer expression profiles made using Affymetrix Human Genome U133 Plus 2.0 Array (NCBI GEO database²⁰, accession GSE65194) for the expression of alpha subunits of NKA. We found abnormalities in *ATP1A1* (coding $\alpha 1$ -subunit) and *ATP1A2* (coding $\alpha 2$ -subunit) expression (Table 1) in breast cancer samples relative to their

expression in normal breast tissue. *ATP1A1* was overexpressed approximately 1.5 times in all groups of breast cancer samples ($p < 0.05$). Coincidentally, *ATP1A2* expression decreased by more than 2 times ($p < 0.05$). There were no differences observed in the expression of *ATP1A3* (coding $\alpha 3$ -subunit).

Methods

Preanalytical procedures consisted of a robust multichip analysis (RMA) algorithm²¹, including background correction, probe set signal integration, and quantile normalization. For this purpose, we used Expression Console 1.4 software (Affymetrix, Inc. USA). We utilized Transcriptome Analysis Console 3.0 software (Affymetrix, Inc. USA) to analyze the obtained CHP files and to detect differentially expressed genes using one-way between subjects ANOVA. Array data for 41 triple negative samples (TNBC group), 30 Her2-positive (Her2 group), 30 Luminal B (Lum B group), 29 Luminal A (Lum A group) breast cancer samples and 11 normal breast tissue samples were investigated.

Conclusions

Using a public microarray dataset we found abnormalities in the expression of *ATP1A1* and *ATP1A2* in breast cancer samples. This may correlate with digitalis anticancer activity, but requires additional research. We expect that our research could help to improve the understanding of predictive and prognostic features of breast cancer.

Data and software availability

Raw data for Table 1 are available at:

<https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE65194&format=file>²².

Expression Console 1.4 software and Transcriptome Analysis Console 3.0 software (Affymetrix, Inc. USA) are available after free customer registration at:

http://www.affymetrix.com/support/technical/software_downloads.affx.

Table 1. NKA genes expression in breast cancer samples relative to normal breast tissue.

Breast cancer group	Lum A	Lum B	Her2	TNBC
Gene	Relative expression/(ANOVA P-value)			
<i>ATP1A1</i>	1.53 (0.009016)	1.38 (0.04454)	1.66 (0.005926)	1.44 (0.015725)
<i>ATP1A2</i>	-2.49 (1.85·10 ⁻⁰⁷)	-2.52 (8.50·10 ⁻⁰⁹)	-2.78 (5.48·10 ⁻⁰⁸)	-2.87 (2.08·10 ⁻¹¹)
<i>ATP1A3</i>	-1.05 (0.429089)	1.03 (0.308298)	-1.04 (0.768041)	-1.04 (0.527878)

Author contributions

AB, FM and MD conceptualized the study, collected data and performed data analysis. All authors were involved in the writing and revision of the draft manuscript and have agreed to the final content.

Competing interests

No competing interests were disclosed.

Grant information

This work was supported by The Ministry of Education and Science of Russian Federation (unique identifier of applied research: RFMEFI60414X0070).

References

1. Siegel RL, Miller KD, Jemal A: **Cancer statistics, 2016.** *CA Cancer J Clin.* 2016; **66**(1): 7–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Perou CM, Sørlie T, Eisen MB, *et al.*: **Molecular portraits of human breast tumours.** *Nature.* 2000; **406**(6797): 747–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Sørlie T, Perou CM, Tibshirani R, *et al.*: **Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.** *Proc Natl Acad Sci U S A.* 2001; **98**(19): 10869–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Sørlie T, Tibshirani R, Parker J, *et al.*: **Repeated observation of breast tumor subtypes in independent gene expression data sets.** *Proc Natl Acad Sci U S A.* 2003; **100**(14): 8418–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Prassas I, Diamandis EP: **Novel therapeutic applications of cardiac glycosides.** *Nat Rev Drug Discov.* 2008; **7**(11): 926–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Schoner W, Scheiner-Bobis G: **Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth.** *Am J Physiol Cell Physiol.* 2007; **293**(2): C509–C36.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Skou JC: **The influence of some cations on an adenosine triphosphatase from peripheral nerves.** *Biochim Biophys Acta.* 1957; **23**(2): 394–401.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Skou JC, Esmann M: **The Na,K-ATPase.** *J Bioenerg Biomembr.* 1992; **24**(3): 249–61.
[PubMed Abstract](#)
9. McDonough AA, Geering K, Farley RA: **The sodium pump needs its beta subunit.** *FASEB J.* 1990; **4**(6): 1598–605.
[PubMed Abstract](#)
10. Mercer RW: **Structure of the Na,K-ATPase.** *Int Rev Cytol.* 1993; **137C**: 139–68.
[PubMed Abstract](#)
11. Blanco G, Mercer RW: **Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function.** *Am J Physiol.* 1998; **275**(5 Pt 2): F633–50.
[PubMed Abstract](#)
12. Babula P, Masarik M, Adam V, *et al.*: **From Na+/K+-ATPase and cardiac glycosides to cytotoxicity and cancer treatment.** *Anticancer Agents Med Chem.* 2013; **13**(7): 1069–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Suhail M: **Na(+), K(+)-ATPase: Ubiquitous Multifunctional Transmembrane Protein and its Relevance to Various Pathophysiological Conditions.** *J Clin Med Res.* 2010; **2**(1): 1–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Suñol M, Cusi V, Cruz O, *et al.*: **Immunohistochemical analyses of alpha1 and alpha3 Na+/K+-ATPase subunit expression in medulloblastomas.** *Anticancer Res.* 2011; **31**(3): 953–8.
[PubMed Abstract](#)
15. Rajasekaran SA, Huynh TP, Wolle DG, *et al.*: **Na,K-ATPase subunits as markers for epithelial-mesenchymal transition in cancer and fibrosis.** *Mol Cancer Ther.* 2010; **9**(6): 1515–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Inge LJ, Rajasekaran SA, Yoshimoto K, *et al.*: **Evidence for a potential tumor suppressor role for the Na,K-ATPase beta1-subunit.** *Histol Histopathol.* 2008; **23**(4): 459–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Espineda C, Seligson DB, James Ball W Jr, *et al.*: **Analysis of the Na,K-ATPase alpha- and beta-subunit expression profiles of bladder cancer using tissue microarrays.** *Cancer.* 2003; **97**(8): 1859–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Rajasekaran SA, Ball WJ Jr, Bander NH, *et al.*: **Reduced expression of beta-subunit of Na,K-ATPase in human clear-cell renal cell carcinoma.** *J Urol.* 1999; **162**(2): 574–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Mijatovic T, Ingrassia L, Facchini V, *et al.*: **Na+/K+-ATPase alpha subunits as new targets in anticancer therapy.** *Expert Opin Ther Targets.* 2008; **12**(11): 1403–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Edgar R, Domrachev M, Lash AE: **Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.** *Nucleic Acids Res.* 2002; **30**(1): 207–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Irizarry RA, Bolstad BM, Collin F, *et al.*: **Summaries of Affymetrix GeneChip probe level data.** *Nucleic Acids Res.* 2003; **31**(4): e15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. GEO accession **GSE65194**, Dubois T: **Expression profiling of breast cancer samples from Institut Curie (Maire cohort) --Affy CDF.** 2015.
[Reference Source](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 10 May 2017

<https://doi.org/10.5256/f1000research.11294.r21728>

© 2017 Chi J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jen-Tsan Ashley Chi

Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, 27708, USA

I think the analysis is appropriate to examine the relative expression of the *ATP1A1* and *ATP1A2* among different breast cancer cells. The data analysis is standard and appropriate. One helpful thing is to validate the findings in other breast cancer expression datasets beyond this discovery dataset. Another relevant thing is whether the abnormal expression of these genes are associated with varying clinical outcomes.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of

expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 21 February 2017

<https://doi.org/10.5256/f1000research.11294.r20402>

© 2017 Fedyanin M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mikhail Fedyanin

Department of Clinical Pharmacology and Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation

Over the past years several papers were published concerning prognostic role of *ATP1A1* expression in hepatocellular carcinoma, lung cancer, and esophageal cancer. The authors of the present study show that increased expression of *ATP1A1* observed at all breast cancer phenotypes compared to normal tissue.

I would like to note that the authors studied gene expression only, but did not appreciate the immunohistochemical (IHC) changes in the content of gene products. In the absence of data of the IHC expression of *ATP1A1*, it is desirable to represent the differences in gene expression of *ATP1A1* compared to referent genes for membrane transporters (<http://bmcmolbiol.biomedcentral.com/articles/10.1186/1471-2199-7-29>). Given a sufficiently large number of patients included in the study, it is interesting to evaluate the prognostic and predictive value of these findings. But I can conclude that this article is interesting for medical oncologists and molecular biologists.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research